Matrix Metalloproteinase-7 Facilitates Insulin-Like Growth Factor Bioavailability through Its Proteinase Activity on Insulin-Like Growth Factor Binding Protein 3

Cancer Research

Volumn 64, Issue 2, 2004, Pages 665-671

  Miyamoto, Shin'Ichi ^a,c   Yano, Keiichi ^b   Sugimoto, Seiji ^b   Ishii, Genichiro ^a   Hasebe, Takahiro ^a   Endoh, Yasushi ^a   Kodama, Keiji ^a   Goya, Masato ^a   Chiba, Tsutomu ^c   Ochiai, Atsushi ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b KYOWA HAKKO KOGYO CO LTD   (Japan)

^c KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MATRILYSIN; PROTEIN KINASE B; PROTEINASE; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER RISK; CARCINOGENESIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; TUMOR CELL LINE;

3T3 CELLS; AMINO ACID SEQUENCE; ANIMALS; BIOLOGICAL AVAILABILITY; CELL LINE, TUMOR; COLONIC NEOPLASMS; ENDOPEPTIDASES; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; KINETICS; MATRIX METALLOPROTEINASE 7; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PHOSPHORYLATION; RECOMBINANT PROTEINS;

EID: 9144232874     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-1916     Document Type: Article

References (65)

1. Sato, H., Takino, T., Okada, Y., Cao, J., Shinagawa, A., Yamamoto, E., and Seiki, M. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature (Lond.), 370: 61-65, 1994.
2. Freije, J. M., Diez-Itza, I., Balbin, M., Sanchez, L. M., Blasco, R., Tolivia, J., and Lopez-Otin, C. Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinoma. J. Biol. Chem., 269: 16766-16773, 1994.
3. Birkedal-Hansen, H. Proteolytic remodeling of extracellular matrix. Curr. Opin. Cell. Biol., 7: 728-735, 1995.
4. Woessner, J. F., Jr., and Taplin, C. Purification and properties of a small latent matrix metalloproteinase of the rat uterus. J. Biol. Chem., 263: 16918-16925, 1988.
5. Miyazaki, K., Hattori, Y., Umenishi, F., Yasumitsu, H., Umeda, M. Purification and characterization of extracellular matrix-degrading metalloproteinase, matrin (pump-1), secreted from human rectal carcinoma cell line. Cancer Res., 50: 7758-7764, 1990.
6. Wilson, C. L., and Matrisian, L. M. Matrilysin: an epithelial matrix metalloproteinase with potentially novel functions. Int. J. Biochem. Cell Biol., 28: 123-136, 1996.
7. Muller, D., Breathnach, R., Engelmann, A., Millon, R., Bronner, G., Flesch. H., Dumont, P., Eber, M., and Abecassis, J. Expression of collagenase-related metalloproteinase genes in human lung or head and neck tumours. Int. J. Cancer. 48: 550-556, 1991.
8. Basset, P., Bellocq, J. P., Wolf, C., Stoll, I., Hutin, P., Limacher, J. M., Podhajcer, O. L., Chenard, M. P., Rio, M. C., and Chambon, P. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature (Lond.), 348: 699-704, 1990.
9. Pajouh, M. S., Nagle, R. B., Breathmach, R., Finch, J. S., Brawer, M. K., and Bowden, G. T. Expression of metalloproteinase genes in human prostate cancer. J. Cancer. Res. Clin. Onco., 117: 144-150, 1991.
10. McDonnell, S., Narve, M., Coffey, R. J., and Matrisian, L. M. Expression and localization of the matrix metalloproteinase pump-1 (MMP-7) in human gastric and colon carcinomas. Mol. Carcinog., 4: 527-533, 1991.
11. Newell, K. J., Witty, J. P., Rodgers, W. H., and Matrisian, L. M. Expression and localization of the matrix-degrading metalloproteinases during colorectal tumorigenesis. Mol. Carcinog., 10: 199-206, 1994.
12. Yamamoto, H., Itoh, F., Adachi, Y., Sakamoto, H., Adachi M, Hinoda Y, and Imai K. Relation of enhanced secretion of active metalloproteinases with tumor spread in human hepatocellular carcinoma. Gastroenterology, 112: 1271-1277, 1997.
13. Grimberg, A., and Cohen, P. Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J. Cell. Physiol., 183: 1-9, 2000.
14. Yu, H., and Rohan, T. Role of insulin-like growth factor family in cancer development and progression. J. Natl. Cancer Inst., 92: 1472-1489, 2000.
15. Furstenberger, G., and Senn, H. J. Insulin-like growth factors and cancer. Lancet Oncol., 3: 298-302, 2001.
16. Sandhu, M. S., Dunger, D. B., and Gionannucci, E. L. Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal carcinogenesis. J. Natl. Cancer Inst., 94: 972-980, 2002.
17. Jones, J. I., and Clemmons, D. R. Insulin-like growth factors and their binding proteins: biological actions. Endocr. Rev., 16: 3-34, 1995.
18. Rajaram, S., Baylink, D. J., and Mohan, S. Insulin-like growth factor binding proteins in serum and other biological fluids: regulations and functions. Endocr. Rev., 18: 801-831, 1997.
19. Arribas, J., Coodly, L., Vollmer, P., Kishimoto, T. K., Rose-John, S., and Massague, J. Diverse cell surface protein ectodomains are shed by a system sensitive to metalloproteinase inhibitors. J. Biol. Chem., 271: 11376-11382, 1996.
20. Whitelock, J. M., Murdoch, A. D., Iozzo, R. V., and Underwood, P. A. The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases. J. Biol. Chem., 271: 10079-10086, 1996.
21. Imai, K., Hiramatsu, A., Fukushima, D., Pierschbacher, M. D., and Okada, Y. Degradation of decorin by matrix metalloproteinases: identification of the cleavage sites, kinetic analyses and transforming growth factor-â 1 release. Biochem. J., 322: 809-814, 1997.
22. Fowlkes, J. L., Enghild, J. J., Suzuki, K., and Nagase, H. Matrix metalloproteinases degrade insulin-like growth factor-binding protein-3 in dermal fibroblast cultures. J. Biol. Chem., 269: 25742-25746, 1994.
23. Manes, S., Llorente, M., Lacalle, R. A., Gomez-Mouton, C., Kremer, L., Mira, E., and Martinez-A, C. The matrix metalloproteinase-9 regulates the insulin-like growth factor-triggered autocrine response in DU-145 carcinoma cells. J. Biol. Chem., 274: 6935-6945, 1999.
24. Thrailkill, K. M., Quarles, L. D., Nagase, H., Suzuki, K., Serra, D. M., and Fowlkes, J. L. Characterization of insulin-like growth factor-binding protein 5-degrading proteases produced throughout murine osteoblast differentiation. Endocrinology, 136: 3527-3533, 1995.
25. Manes, S., Mira, E., Barbacid, M. M., Cipres, A., Fernandez-Resa, P., Buesa, J. A., Merida, I., Aracil, M., Marquez, G., and Martinez-A, C. Identification of insulin-like growth factor-binding protein-1 as a potential physiological substrate for human stromelysin-3. J. Biol. Chem., 272: 25706-25712, 1997.
26. Vermes, I., Haanen, C., and Reutelingsperger, C. P. M. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J. Immunol. Methods, 184: 39-51, 1995.
27. Firth, S. M., and Baxter, R. C. The role of glycosylation in the action of IGFBP-3. Prog. Growth Factor Res., 6: 223-229, 1995.
28. Kulik, G., Klippel, A., and Weber, M. J. Antiapoptotic signaling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Mol. Cell. Biol., 17: 1595-1606, 1997.
29. Kulik, G., and Weber, M. J. Akt-dependent and -independent survival signaling pathways utilized by insulin-like growth factor I. Mol. Cell. Biol., 18: 6711-6718, 1998.
30. Liu, A. X., Testa, J. R., Hamilton, T. C., Jove, R., Nicosia, S. V., and Cheng, J. Q., AKT2, a member of the protein kinase B family, is activated by growth factors, v-Ha-ras, and v-src through phosphatidylinositol 3-kinase in human ovarian epithelial cancer cells. Cancer Res., 58: 2973-2977, 1998.
31. Alessi, D. R., Andjelkovic, M., Caudwell, B., Cron, P., Morrice, N., Cohen, P., and Hemmings, B. A. Mechanism of activation of protein kinase B by insulin and IGF-I. EMBO J., 15: 6541-6551, 1996.
32. Sires, U. I., Murphy, G., Baragi, V. M., Fliszar, C. J., Welgus, H. G., and Senior, R. M. Matrilysin is much more efficient than other matrix metalloproteinases in the proteolytic inactivation of ál-antitrypsin. Biochem. Biophys. Res. Commun., 204: 613-620, 1994.
33. Zhang, Z., Winyard, P. G., Chidwick, K., Murphy, G., Wardell, M., Carrell, R. W., and Blake, D. R. Proteolysis of human native and oxidised ál-proteinase inhibitor by matrilysin and stromelysin. Biochim. Biophys. Acta, 1199: 224-228, 1994.
34. Gearing, A. J., Beckett, P., Christdoulou, M., Churchill, M., Clements, J., Davidson, A. H., Drummond, A. H., Galloway, W. A., Gilbert, R., Gordon, J. L., Leber, T. M., Mangan, M., Miller, K., Nayee, P., Owen, K., Patel, S., Thomas, W., Wells, G., Wood, L. M., and Wooley, K. Processing of tumour necrosis factor-á precursor by metalloproteinases. Nature (Lond.), 370: 555-557, 1994.
35. Marcotte, P. A., Kozan, I. M., Dorwin, S. A., and Ryan, J. M. The matrix metalloproteinase pump-1 catalyzes formation of low molecular weight (pro)urokinase in cultures of normal human kidney cells. J. Biol. Chem., 267: 13803-13806, 1992.
36. Chandler, S., Coates, R., Gearing, A., Lury, J., Wells, G., and Bone, E. Matrix metalloproteinases degrade myelin basic protein. Neurosci. Lett., 201: 223-226. 1995.
37. Powell, W. C., Fingleton, B., Wilson, C. L., Boothby, M., and Matrisian, L. M. The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis. Curr. Biol., 9: 1441-1447, 1999.
38. Noe, V., Fingleton, B., Jacobs, K., Crawford, H. C., Vermeulen, S., Steelant, W., Bruyneel, E., Matrisian, L. M., and Mareel, M. Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. J. Cell. Sci., 114: 111-118, 2001.
39. Agnihorti, R., Crawford, H. C., Haro, H., Matrisian, L. M., Havrda, M. C., and Liaw, L. Osteopontin, a novel substrate for matrix metalloproteinase-3 (stromelysin-1) and matrix metalloproteinase-7 (matrilysin). J. Biol. Chem., 276: 28261-28267, 2001.
40. Hashimoto, G., Inoki, I., Fujii, Y., Aoki, T., Ikeda, E., and Okada, Y. Matrix metalloproteinases cleave connective tissue growth factor and reactivate angiogenic activity of vascular endothelial growth factor 165. J. Biol. Chem., 277: 36288-36295, 2002.
41. Imai, K., Yokohama, Y., Nakanishi, I., Ohuchi, E., Fujii, Y., Nakai, N., and Okada, Y. Matrix metalloproteinase 7 (matrilysin) from human rectal carcinoma cells. Activation of the precursor, interaction with other matrix metalloproteinases and enzymic properties. J. Biol. Chem., 270: 6691-6697, 1995.
42. Netzel-Arnett, S., Sang, Q. X., Moore, W. G., Navre, M., Birkedal-Hansen, H., and Van Wart, H. E. Comparative sequence specificities of human 72- and 92-kDa gelatinases (type IV collagenases) and PUMP (matrilysin). Biochemistry, 32: 6427-6432, 1993.
43. Lalou, C., Sawamura, S., Segovia, B., Ogawa, Y., and Binoux, M. Proteolytic fragments of insulin-like growth factor binding protein-3: N-terminal sequences and relationships between structure and biological activity. CR. Acad. Sci. III., 32: 621-628, 1997.
44. Bang, P. Serum proteolysis of IGFBP-3. Prog. Growth Factor Res., 6: 285-292, 1995.
45. Muller, H. L., Oh, Y., Gargosky, S. E., Wilson, K. F., Lehrnbecher, T., and Rosenfeld, R. G. Insulin-like growth factor binding protein-3 concentrations and insulin-like growth factor binding protein-3 protease activity in sera of patients with malignant solid tumors or leukemia. Pediatr. Res., 35: 720-724, 1994.
46. Baciuchka, M., Remacle-Bonnet, M., Garrouste. F., Favre, R., Sastre, B., and Pommier, G. Insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) proteolysis in patients with colorectal cancer: possible association with the metastatic potential of the tumor. Int. J. Cancer, 79: 460-467, 1998.
47. Brennan, B. M., Gill, M., Pennells, L., Eden, O. B., Thomas, A. G., and Clayton, P. E. Insulin-like growth factor 1, IGF binding protein 3, and IGFBP protease activity: relation to anthropometric indices in solid tumours or leukaemia. Arch. Dis. Child. 80: 226-230, 1999.
48. Long, L., Nip, J., and Brodt. P. Paracrine growth stimulation by hepatocyte-derived insulin-like growth factor-1: a regulatory mechanism for carcinoma cells metastatic to the liver. Cancer Res., 54: 3732-3737, 1994.
49. Kawamoto, K., Onodera, H., Kan, S., Kondo, S., and Imamura, M. Possible paracrine mechanism of insulin-like growth factor-2 in the development of liver metastases from colorectal carcinoma. Cancer (Phila.), 85: 18-25, 1999.
50. Hakam, A., Yeatman, T. J., Lu, L., Mora, L., Marcet, G., Nicosia, S. V., Karl, R. C., and Coppola, D. Expression of insulin-like growth factor-1 receptor in human colorectal cancer. Hum. Pathol., 30: 1128-1133, 1999.
51. Long, L., Rubin, R., Baserga, R., and Brodt, P. Loss of the metastatic phenotype in murine carcinoma cells expressing an antisense RNA to the insulin-like growth factor receptor. Cancer Res., 55: 1006-1009, 1995.
52. Dunn, S. E., Ehrlich, M., Sharp, N. J. H., Reiss, K., Solomon, G., Hawkins, R., Baserga, R., and Barrett, J. C. A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer. Cancer Res., 58: 3353-3361, 1998.
53. Hasegawa, S., Koshikawa, N., Momiyama, N., Moriyama, K., Ichikawa, Y., Ishikawa, T., Mitsuhashi, M., Shimada, H., and Miyazaki, K. Matrilysin-specific antisense oligonucleotide inhibits liver metastasis of human colon cancer cells in a nude mouse model. Int. J. Cancer, 76: 812-816, 1998.
54. Mori, M., Barnard, G. F., Mimori, K., Ueo, H., Akiyoshi, T., and Sugimachi, K. Overexpression of matrix metalloproteinase-7 mRNA in human colon carcinomas. Cancer (Phila.), 75: 1516-1519, 1995.
55. Ishikawa, T., Ichikawa, Y., Mitsuhashi, M., Momiyama, N., Chishima, T., Tanaka, K., Yamaoka, H., Miyazakic, K., Nagashima, Y., Akitaya, T., and Shimada, H. Matrilysin is associated with progression of colorectal tumor. Cancer Lett., 107: 5-10, 1996.
56. Adachi, Y., Yamamoto, H., Itof, F., Hinoda, Y., Okada, Y., and Imai, K. Contribution of matrilysin (MMP-7) to the metastatic pathway of human colorectal cancers. Gut, 45: 252-258, 1999.
57. Ma, J., Pollak, M. N., Giovannucci, E., Chan, J. M., Tao, Y., Hennekens, C. H., and Stampfer, M. J. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J. Natl. Cancer Inst., 91: 620-625, 1999.
58. Hankinson, S. E., Willett, W. C., Colditz, G. A., Hunter, D. J., Michaud, D. S., Deroo, B., Rosner, B., Speizer, F. E., and Pollak, M. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet, 351: 1393-1396, 1998.
59. Chan, J. M., Stampfer, M. J., Giovannucci, E., Gann, P. H., Ma, J., Wilkinson, P., Hennekens, C. H., and Pollak, M. Plasma insulin-like growth factor-1 and prostate cancer risk: a prospective study. Science (Wash. DC), 279: 563-566. 1998.
60. Wolk, A., Mantzoros, C. S., Andersson, S. O., Bergstorm, R., Signorello, L. B., Lagiou, P., Adami, H. O., and Trichopoulos, D. Plasma insulin-like growth factor-1 and prostate cancer risk: a prospective study. J. Natl. Cancer Inst., 90: 911-915, 1998.
61. Yu, H., Spitz, M. R., Mistry, J., Gu, J., Hong, W. K., and Wu, X. Plasma levels of insulin-like growth factor-1 and lung cancer risk: a case-control analysis. J. Natl. Cancer Inst., 91: 151-156, 1999.
62. Wilson, C. L., Heppner, K. J., Labosky, P. A., Hogan, B. L. M., and Matrisian, L. M. Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc. Natl. Acad. Sci. USA, 94: 1402-1407, 1997.
63. Hassan, A. B., and Howell, J. A. Insulin-like growth factor II supply modifies growth of intestinal adenoma in Apc(Min/+) mice. Cancer Res., 60: 1070-1076, 2000.
64. Rubini, M., Hongo, A., D'Ambrosio, C., and Baserga, R. The IGF-I receptor in mitogenesis and transformation of mouse embryo cells: role of receptor number. Exp. Cell Res., 230: 284-292, 1997.
65. Peretz, S., Kim, C., Rockwell, S., Baserga, R., and Glazer, P. M. IGFI receptor expression protects against microenvironmental stress found in the solid tumor. Radiation Res., 158: 174-180, 2002.